Floatz logo

Bmn 110

MPS IV A

BioMarin PharmaceuticalPhase 3Dormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the MPS IV A cohort.

Asset / SponsorPhaseRating
Losartan
Hospital de Clinicas de Porto Alegre
Phase 2CCC
IDURONIDASE, .ALPHA.-L-(8-HISTIDINE) (HUMAN)
University of California, San Francisco
Phase 1CC
CHONDROITIN SULFATASE
BioMarin Pharmaceutical
D
Bmn 110
BioMarin Pharmaceutical
Phase 3NR

Same molecule, other indications

Bmn 110 is also rated in:

mucopolysaccharidosis type 4ADormant
NR
Indicative ·
/ 100
View asset →
Morquio A SyndromeDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →